2019 was another big year for novel drug approvals (48 in total) though it wasn’t the record year of 2018 (with 59). The overall explosion in large molecule modalities continued with year with 12 novel large molecules, including 3 monoclonal antibodies, a recombinant fusion protein (Reblozyl), 3 ADCs, an siRNA drug (Givlaari), an antisense oligonucleotide (Vyondys 53), a nanobody (Cablivi) and a single-chain antibody (Beovu). Here’s a visual summary of the 12 large molecules approved in 2019 along with two peptides.1

To subscribe and download the poster in PDF format, click below:

2019 Novel Large Molecule and Peptide Drug Approvals

Subscribe to our Drug Hunter mailing list to receive a link to download a higher resolution PDF of the above image,

send download link to:

I confirm that I have read and agree to the Terms of Use and Privacy Policy.

For a graphic of 2019 small molecule drugs, see this previous post. To compare these statistics to last year, see this previous post.

Explore drughunter.com for more.

  1. This doesn’t include biologic agents like vaccines or gene therapies like Zolgensma, covered under the FDA’s Biologic License Application Approvals.